CA 15-3 Test Explained: Normal Range, High Levels, Breast Cancer Monitoring & Report Reading (India 2026) | CA 15-3 टेस्ट गाइड

CA 15-3 Test Explained: Normal Range, High Levels, Breast Cancer Monitoring & Report Reading (India 2026)

CA 15-3 टेस्ट गाइड: नॉर्मल रेंज, Breast Cancer Monitoring — High Levels के कारण और Report Reading

A plain-language guide for patients & families · भारतीय मरीज़ों के लिए सरल मार्गदर्शिका

Your oncologist has ordered CA 15-3 every 3 months since completing chemotherapy for breast cancer — and your latest result shows a rise from 28 to 47 U/mL. Or you are a woman with no history of breast cancer whose health checkup panel included CA 15-3, and it has come back at 42 U/mL — mildly elevated — and you are anxious about what this means. CA 15-3 is the most widely used blood tumour marker for breast cancer — but its role is almost exclusively in monitoring women already diagnosed with breast cancer, not in screening healthy women. Understanding this distinction prevents enormous unnecessary anxiety from mildly elevated results in the general population.

CA 15-3 का role primarily: already diagnosed breast cancer वाली महिलाओं में treatment monitoring और recurrence detection। Healthy women में screening के लिए नहीं। यह distinction समझना mildly elevated results से unnecessary anxiety को prevent करता है।

 Table of Contents / विषय सूची

1. What Is CA 15-3? / CA 15-3 क्या है?
2. Normal Range & Levels
3. Why CA 15-3 Is NOT a Screening Test
4. Monitoring Treatment Response & Recurrence
5. Causes of High CA 15-3 — Cancer & Benign
6. India Context — Breast Cancer Burden & Late Diagnosis
7. Test Preparation Checklist
8. Frequently Asked Questions / FAQ

Image 1: CA 15-3 — the breast cell activity thermometer. CA 15-3 (Cancer Antigen 15-3) is a fragment of the MUC1 glycoprotein (Mucin-1), a large protein normally found on the surface of breast ductal epithelial cells. In normal breast tissue, tiny amounts of MUC1 are shed into the bloodstream (normal CA 15-3 below 25–30 U/mL). When breast cancer cells become cancerous and proliferating rapidly, they shed dramatically more MUC1 into the bloodstream — causing CA 15-3 to rise. Think of CA 15-3 as a thermometer of breast cell activity: low readings = quiet normal breast epithelium; high readings = high cellular activity from either cancer proliferation, treatment response changes, or benign breast inflammation. The critical limitation: CA 15-3 is only elevated in approximately 20–30% of early breast cancer cases — it does not "detect" most breast cancers at the stage when they are curable. It is most sensitive (elevated in 60–80%) in advanced, metastatic breast cancer — when the tumour burden is large enough to produce measurable amounts in blood.

NOT a screening test CA 15-3 sensitivity for early breast cancer (Stage I–II) is only 20–30% — it misses 70–80% of early cancers. It is not recommended for screening by any major organisation (ASCO, ESMO, NCCN). The only validated breast cancer screening tests are mammography and clinical breast examination.

Monitoring #1 use CA 15-3's primary clinical value is in women already diagnosed with breast cancer — monitoring chemotherapy response (falling CA 15-3 = responding), detecting recurrence during post-treatment surveillance (rising CA 15-3 often precedes positive imaging by 2–9 months), and tracking metastatic disease activity.

Breast cancer #1 Breast cancer is the most common cancer in Indian women — estimated 200,000+ new cases annually — overtaking cervical cancer since 2018. India's breast cancer is diagnosed at significantly later stages than Western countries, with only 15–20% detected at Stage I–II vs 60–70% in the US. This late diagnosis drives the need for better monitoring tools like CA 15-3.

---

What Is CA 15-3?

CA 15-3 is a tumour-associated antigen — specifically, a shed fragment of the MUC1 (Mucin-1) glycoprotein detected in blood by two monoclonal antibodies (115D8 and DF3). MUC1 is a large, heavily glycosylated transmembrane protein expressed on the apical surface of ductal epithelial cells of the breast, lung, ovary, pancreas, and other glands. In cancer, MUC1 is overexpressed, aberrantly glycosylated, and shed at dramatically higher rates into the bloodstream. CA 15-3 and CA 27.29 (BR 27.29) are two assays measuring different epitopes of the same MUC1 molecule — they provide equivalent clinical information and are used interchangeably in practice.

CA 15-3 = MUC1 glycoprotein का shed fragment, blood में detect होता है। MUC1 = breast, lung, ovary, pancreas ductal cells पर। Cancer में: overexpressed + aberrantly glycosylated + dramatically more shed। CA 27.29 (BR 27.29) = same MUC1 molecule का different epitope — clinically equivalent।

CA 15-3 vs other breast cancer markers — what each adds:

• CA 15-3 (MUC1 fragment): Primary breast cancer monitoring marker. Elevated in 60–80% of metastatic breast cancer. Best for serial monitoring of treatment response and recurrence detection. Also mildly elevated in some benign conditions.
• CEA (Carcinoembryonic Antigen): Non-specific GI and breast cancer marker. Sometimes elevated alongside CA 15-3 in breast cancer — particularly ER-positive (hormone receptor positive) metastatic disease. Combined CA 15-3 + CEA improves sensitivity for metastatic breast cancer recurrence detection.
• CA 125: Primarily ovarian cancer marker but sometimes elevated in breast cancer with peritoneal/serosal metastases. See our CA-125 guide.
• HER2 (Serum): Shed extracellular domain of HER2 receptor — elevated when HER2-positive breast cancer is active. Rising serum HER2 during trastuzumab (Herceptin) treatment may suggest resistance development.
• Practical approach: In India, most oncologists use CA 15-3 as the primary monitoring marker. Adding CEA to the panel improves detection sensitivity at modest additional cost.

CA 15-3: primary breast cancer monitoring। CEA: alongside CA 15-3 for better sensitivity, especially ER+ metastatic। CA 125: peritoneal metastases में। HER2 serum: HER2+ disease monitoring। India में: CA 15-3 primary + CEA add करना = improved sensitivity।

---

Normal Range & Levels

*Reference ranges vary between labs and assay platforms. Most Indian NABL labs use either 25 U/mL or 30 U/mL as the upper limit of normal. Always compare against your specific lab's reference range. Units: U/mL (= kU/L).

Upper limit of normal: most Indian labs 25 U/mL या 30 U/mL। अपनी lab की range use करें। Units: U/mL।

CA 15-3 Level (U/mL)	Classification	Clinical Context	Action
<25–30 U/mL	Normal	In healthy women: normal. In breast cancer patients on surveillance: reassuring — no evidence of active disease. Note: 20–30% of early breast cancer patients have normal CA 15-3.	Routine monitoring as per oncologist schedule. No immediate action.
30–60 U/mL	Mildly elevated	In healthy women: most commonly benign (liver disease, benign breast disease, pregnancy, lactation). In breast cancer survivors: warrants comparison to previous baseline and clinical correlation.	Compare to previous values (trend matters more than single value). Check LFT. Clinical breast examination and imaging if symptoms. Oncology review for cancer patients.
60–200 U/mL	Significantly elevated	In known breast cancer patients: suggests active disease — metastatic recurrence or progression. In newly tested women: warrants full clinical workup (mammography, breast examination, CT/MRI, biopsy if warranted).	Urgent oncology referral for known breast cancer patients. Full clinical and imaging workup for new presentations. Serial CA 15-3 trend essential.
>200 U/mL	Markedly elevated	Strongly associated with advanced/metastatic breast cancer in known breast cancer patients. Very high levels (>500 U/mL) correlate with large tumour burden and widespread metastases.	Urgent CT staging. Systemic treatment initiation or modification. Palliative care discussion if appropriate.

⚠️ The trend matters far more than any single value:

A CA 15-3 of 35 U/mL (mildly above normal) in a breast cancer survivor is less concerning than a CA 15-3 of 22 U/mL (technically normal) that has risen from a previous baseline of 8 U/mL. A 25% or greater rise from baseline — even within the "normal" range — on two consecutive measurements taken 4–6 weeks apart is considered a significant change warranting clinical investigation. Conversely, a CA 15-3 of 45 U/mL in a patient on chemotherapy that has fallen from a previous 180 U/mL represents an excellent treatment response, not a cause for alarm. Serial trends, not isolated numbers, are the clinical message of CA 15-3.

Single value से trend ज़्यादा important। Baseline से 25%+ rise (even within "normal" range) = two consecutive measurements 4–6 weeks apart पर significant। Chemotherapy में 180 → 45 = excellent response। Serial trends = CA 15-3 का clinical message।

---

Why CA 15-3 Is NOT a Screening Test

Image 2: CA 15-3 elevation — benign vs malignant causes. The most important clinical insight is that CA 15-3 is not breast-cancer-specific. Many benign conditions cause mild CA 15-3 elevation: liver diseases (cirrhosis, hepatitis — the liver clears CA 15-3, so liver dysfunction causes accumulation), benign breast disease (fibrocystic changes, mastitis), pregnancy and lactation (physiological MUC1 upregulation), inflammatory conditions (SLE, rheumatoid arthritis), and other cancers (ovarian, lung, colon, pancreatic). The key principle: in a healthy woman with no breast symptoms and a mildly elevated CA 15-3 (30–60 U/mL), the probability that this represents early breast cancer is very low — and the probability of a benign explanation is high. Mammography and clinical breast examination — not CA 15-3 — are the validated screening tools. In a woman already diagnosed with breast cancer, the same mild elevation has a completely different clinical significance.

CA 15-3's failure as a screening test comes from three fundamental limitations that cannot be overcome by lowering the threshold or ordering it more frequently. These limitations make it unsuitable for use in healthy women without known breast disease.

CA 15-3 three fundamental limitations के कारण screening test के रूप में fail होता है। Healthy women में use के लिए unsuitable।

Limitation 1 — Low sensitivity for early (curable) cancer Early Cancer में Low Sensitivity

CA 15-3 is elevated in only 20–30% of Stage I–II breast cancer cases. Stage I breast cancer — when confined to the breast and highly curable (5-year survival >95%) — has a CA 15-3 elevation rate of only 15–20%. A healthy woman with Stage I breast cancer has a 80–85% chance of having a completely normal CA 15-3. If used for screening, the test would miss the vast majority of the most curable cancers — exactly the opposite of what a useful screening test should do. The test does better with advanced disease (60–80% sensitivity in Stage IV) — but by then, the window for curative treatment has usually passed. Stage I–II breast cancer में sensitivity: 20–30% only। Stage I: 80–85% chance of normal CA 15-3। Most curable cancers miss → screening के रूप में worse than useless। Advanced disease (Stage IV) में better (60–80%) — लेकिन curative window gone।

Limitation 2 — High false-positive rate from benign conditions Benign Conditions से High False-Positive Rate

If CA 15-3 were used to screen millions of Indian women, the vast majority of elevated results would be from benign conditions: liver disease (endemic in India — hepatitis B, hepatitis C, NAFLD, cirrhosis), benign breast disease (extremely common — fibrocystic changes in 30–50% of premenopausal women), pregnancy and lactation (up to 100 U/mL physiologically), inflammatory conditions, and other cancers. Each false-positive would trigger unnecessary anxiety, unnecessary biopsies, unnecessary imaging — causing physical and psychological harm to thousands of women who do not have breast cancer. This is the "screening harm" that oncology societies explicitly warn about with CA 15-3. India में millions women को screen करें → vast majority elevated results = benign: liver disease (Hepatitis B/C, NAFLD endemic), benign breast disease (30–50% premenopausal women), pregnancy/lactation (100 U/mL physiological), other cancers। Each false-positive = unnecessary biopsy + anxiety + imaging — physical और psychological harm।

Limitation 3 — No evidence that CA 15-3 screening improves survival Screening से Survival Improve नहीं होती

Critically, no randomised controlled trial has ever demonstrated that measuring CA 15-3 in healthy women reduces breast cancer mortality. The only breast cancer screening interventions with proven mortality benefit are mammography (30–35% mortality reduction) and clinical breast examination. This is why ASCO (American Society of Clinical Oncology), ESMO, NCCN, and Indian oncology bodies all explicitly recommend: CA 15-3 should NOT be used for breast cancer screening in the general population. It belongs in the oncologist's clinic after diagnosis — not in a wellness health checkup panel. Randomised trial नहीं: CA 15-3 screening से breast cancer mortality reduce होती है। Proven screening: Mammography (30–35% mortality reduce) + clinical breast examination। ASCO + ESMO + NCCN + Indian guidelines: CA 15-3 = NOT for screening। Oncologist's clinic में post-diagnosis।

What should be used for breast cancer screening instead? Breast Cancer Screening के लिए क्या Use करें

Validated breast cancer screening for Indian women:

• Monthly self-breast examination (SBE): from age 20 — awareness of normal breast texture and prompt reporting of new lumps, nipple discharge, skin changes
• Annual clinical breast examination (CBE) by a doctor — from age 25–30
• Annual mammography — from age 40–45 (or earlier with family history of breast cancer or BRCA mutation)
• Breast MRI — for BRCA1/BRCA2 mutation carriers and women with strong family history (annual from age 25–30)
• BRCA1/BRCA2 genetic testing — for women with first-degree relatives with breast or ovarian cancer before age 50

Validated screening: Monthly self-breast examination (age 20+), Annual clinical breast examination (age 25+), Annual mammography (age 40–45+), Breast MRI (BRCA mutation carriers from age 25), BRCA1/2 genetic testing (family history)।

---

Monitoring Treatment Response & Recurrence

Image 3: The CA 15-3 monitoring curve — what the numbers mean over the breast cancer treatment journey. At diagnosis: CA 15-3 is elevated (especially in metastatic disease). During effective chemotherapy: CA 15-3 falls — a 50% or greater reduction from baseline after 1–2 cycles is a "marker response" associated with improved survival. Post-surgery/complete remission: CA 15-3 returns to normal (below 30 U/mL). During surveillance: CA 15-3 is measured every 3–6 months; a rising trend (especially 25% above the previous nadir on two consecutive measurements) is the earliest biochemical signal of recurrence — typically appearing 2–9 months before CT or PET imaging becomes positive, allowing earlier treatment initiation. The paradoxical early rise: some patients show a transient CA 15-3 spike in the first 2–6 weeks after starting chemotherapy — this is called the "flare phenomenon" (rapid tumour cell lysis releases stored MUC1 into the bloodstream) and should not be misinterpreted as treatment failure. Always confirm CA 15-3 trends with imaging.

During chemotherapy — what falling CA 15-3 means Chemotherapy में — Falling CA 15-3 का अर्थ

In women with metastatic breast cancer or high CA 15-3 at diagnosis, serial CA 15-3 measurements every 6–8 weeks during chemotherapy track treatment response:

• Falling CA 15-3 (>50% reduction after 2 cycles) = tumour responding to treatment → continue current regimen
• Stable CA 15-3 (within 25% of baseline) = stable disease — CT imaging needed to confirm
• Rising CA 15-3 (>25% above nadir on two occasions) = likely progression — CT imaging and regimen change needed
• Transient spike in weeks 1–4 (flare) = normal — tumour cell lysis releasing MUC1; do NOT change treatment; recheck at week 6–8

Chemotherapy monitoring: >50% fall after 2 cycles = responding। <25% change = stable। >25% rise above nadir (two occasions) = likely progression → CT + regimen change। Weeks 1–4 spike = flare (normal) — treatment change नहीं।

Post-treatment surveillance — the most important use Post-Treatment Surveillance — Most Important Use

After completing curative treatment (surgery + chemotherapy + radiation) for early breast cancer, CA 15-3 surveillance is used to detect recurrence as early as possible. The Indian ICMR and most breast oncology units recommend serial CA 15-3 (combined with CEA) every 3–6 months for 3–5 years after treatment. The clinical value: CA 15-3 typically rises 2–9 months before imaging detects recurrence, giving a window for earlier treatment initiation. However, the decision to change treatment must be based on imaging confirmation — a rising CA 15-3 alone is not sufficient to alter treatment. Standard protocol on rising CA 15-3 during surveillance: CT chest/abdomen/pelvis + bone scan (or PET-CT) to localise the recurrence site. Post-treatment surveillance: CA 15-3 + CEA हर 3–6 months, 3–5 years। CA 15-3 rises 2–9 months before imaging detects recurrence। Rising CA 15-3 alone = treatment change नहीं। Protocol: CT + bone scan या PET-CT → recurrence site localise करें।

---

Causes of High CA 15-3 — Cancer & Benign

CA 15-3 is not breast-cancer-specific. Many conditions elevate CA 15-3 — understanding the full list is essential for interpreting mildly elevated results without panic and without false reassurance.

CA 15-3 breast-cancer-specific नहीं। Many conditions elevate करती हैं — full list समझना ज़रूरी: mild elevation से panic नहीं, और false reassurance नहीं।

Cause	Typical CA 15-3 Level	Notes
Metastatic breast cancer	60–5,000+ U/mL	Sensitivity 60–80% for metastatic disease. Elevated in most metastatic patients. Primary clinical use: monitoring.
Early breast cancer (Stage I–II)	Usually normal; mildly elevated in 20–30%	Poor sensitivity for early-stage — most patients have normal CA 15-3 even with confirmed cancer.
Ovarian cancer	30–200 U/mL	CA 15-3 elevated in 60–70% of advanced ovarian cancer. CA 125 is the preferred marker for ovarian cancer.
Lung cancer	30–150 U/mL	Elevated in adenocarcinoma subtypes. MUC1 expressed on lung epithelium.
Liver disease (cirrhosis, hepatitis B/C, NAFLD)	25–80 U/mL	Most common benign cause in India. Impaired hepatic clearance of CA 15-3. Check LFT alongside.
Benign breast disease	25–50 U/mL	Fibrocystic breast disease, mastitis, benign fibroadenoma — mild MUC1 shedding. Very common in premenopausal Indian women.
Pregnancy and lactation	Up to 100 U/mL (physiological)	MUC1 physiologically upregulated during pregnancy and lactation. Always disclose before testing. Do NOT interpret as cancer.
Autoimmune disease (SLE, RA)	25–60 U/mL	Inflammatory cytokines upregulate MUC1 expression. Mild elevation.
Endometriosis	25–50 U/mL	Ectopic endometrial MUC1 production. Can mimic ovarian or breast pathology on tumour marker panels.

---

India Context — Breast Cancer Burden & Late Diagnosis

India में breast cancer और CA 15-3 से related key clinical contexts:

India's breast cancer crisis — late diagnosis and poor awareness India का Breast Cancer Crisis

Breast cancer is now India's most common cancer in women with an estimated 200,000+ new cases annually. The survival statistics are starkly worse than Western countries: 5-year survival in India is approximately 60% vs 90% in the US — primarily because only 15–20% of Indian breast cancers are diagnosed at Stage I–II (localised, highly curable) compared to 60–70% in developed countries. Reasons for late diagnosis in India: low awareness of breast cancer symptoms; cultural barriers to breast self-examination and discussion; limited mammography access in rural areas; poor adherence to screening guidelines; and the misconception that a "normal CA 15-3" rules out breast cancer (which is false). The most impactful action for any Indian woman: regular self-breast examination monthly + annual mammography from age 40 + prompt reporting of any breast lump, nipple discharge, or skin change to a doctor — regardless of CA 15-3 value. India में breast cancer 200,000+ cases/year। 5-year survival India: 60% vs US: 90%। Reason: 15–20% Stage I–II में diagnose (vs US में 60–70%)। Late diagnosis: low awareness, cultural barriers, limited mammography access, "normal CA 15-3 = no cancer" misconception। Most impactful action: monthly self-examination + annual mammography from age 40 + prompt reporting।

CA 15-3 in Indian oncology practice — how it is used Indian Oncology Practice में CA 15-3 का Use

In India's cancer centres (Tata Memorial Mumbai, AIIMS Delhi, Kidwai Institute Bangalore), CA 15-3 is used for:

• Baseline measurement at breast cancer diagnosis — establishes the individual patient's marker baseline (particularly important in metastatic patients)
• Chemotherapy monitoring — every 2–3 cycles; falling CA 15-3 confirms response without waiting for CT scan
• Post-treatment surveillance — every 3–6 months for 5 years; combined with clinical examination and annual mammography
• Metastatic disease monitoring — monthly or bimonthly in active treatment
• Hormone therapy monitoring — in ER+ breast cancer on tamoxifen or aromatase inhibitors, CA 15-3 tracks response

The most common misuse seen in India: ordering CA 15-3 in wellness checkup packages for women with no breast symptoms or history — creating unnecessary anxiety when mildly elevated values appear. Indian cancer centres में CA 15-3 uses: Baseline at diagnosis, Chemotherapy monitoring (every 2–3 cycles), Post-treatment surveillance (every 3–6 months, 5 years), Metastatic disease monitoring, Hormone therapy monitoring। Most common misuse: wellness checkup panels में order करना without indication।

---

Test Preparation Checklist / टेस्ट की तैयारी

CA 15-3 test की accurate और reproducible measurement के लिए preparation और serial testing protocol:

• ✓
  No specific fasting required — but consistent timing with previous tests is essential for serial monitoring. CA 15-3 is not significantly affected by food. However, for serial monitoring (the primary use), always collect at the same time of day under the same conditions as previous measurements — variations in daily CA 15-3 fluctuations are minimised by consistent collection timing. If adding LFT (liver function) to the panel, 8–12 hours fasting is required for the LFT component. Fasting required नहीं। Serial monitoring में: same time of day, same conditions → consistent। LFT साथ order करें तो: 8–12 hours fasting।
• ✓
  Always use the same lab and assay platform for serial monitoring. This is perhaps the single most critical rule for CA 15-3 monitoring. Different labs use different immunoassay platforms (CLIA, ECLIA, ELISA) that give systematically different absolute values for the same sample. A patient with CA 15-3 of 42 U/mL at Lab A may have a value of 61 U/mL at Lab B — not because the disease has progressed but because of inter-assay variation. For all serial monitoring: use the same NABL-accredited lab, same assay method, every time. If the patient must change labs, run a parallel sample at both labs to establish a conversion factor. Serial monitoring में: हमेशा same NABL lab + same assay platform। Different labs: systematically different values (Lab A = 42, Lab B = 61 — disease progression नहीं, assay variation)। Lab change करना पड़े: parallel sample दोनों labs में → conversion factor establish करें।
• ✓
  Disclose pregnancy and breastfeeding — physiological CA 15-3 elevation up to 100 U/mL. MUC1 is physiologically upregulated during pregnancy and lactation — a breastfeeding woman can have CA 15-3 of 50–100 U/mL as a completely normal finding. If pregnant or breastfeeding, the CA 15-3 result is uninterpretable for cancer monitoring purposes. Inform the lab when submitting — the report should note the physiological context. Pregnancy और breastfeeding disclose करें। MUC1 physiologically upregulated → CA 15-3 50–100 U/mL = completely normal। Pregnant/lactating में: result uninterpretable for monitoring। Lab को inform करें।
• ✓
  Add CEA to the panel for breast cancer monitoring — combined sensitivity is higher. CA 15-3 alone misses some recurrences where CEA rises while CA 15-3 remains stable, and vice versa. The combination of CA 15-3 + CEA has approximately 10–15% higher sensitivity for detecting metastatic breast cancer recurrence than either marker alone. This is endorsed by ESMO breast cancer guidelines and widely practiced at major Indian cancer centres. The addition of CEA adds minimal cost to the panel. Breast cancer monitoring में CEA add करें। CA 15-3 alone: some recurrences miss (CEA rises, CA 15-3 stable)। CA 15-3 + CEA = 10–15% higher sensitivity। ESMO endorsed + Indian cancer centres में practiced। CEA add करने पर minimal additional cost।
• ✓
  Never interpret a single elevated CA 15-3 as proof of recurrence — always confirm with imaging. The standard clinical protocol for a rising CA 15-3 during surveillance: (1) Repeat CA 15-3 in 4–6 weeks to confirm the rise is genuine and not a laboratory or biological fluctuation; (2) If the repeat confirms a rising trend (25% above nadir on two consecutive measurements): proceed to CT chest/abdomen/pelvis + bone scan or PET-CT; (3) Tissue biopsy of the suspected recurrence site if imaging confirms a lesion; (4) Treatment decision based on biopsy findings, receptor status, and imaging. Never start chemotherapy, hormonal therapy, or bisphosphonates solely on the basis of a rising CA 15-3 without imaging confirmation. Single elevated CA 15-3 = recurrence proof नहीं। Protocol: 4–6 weeks बाद repeat → confirmed rising trend → CT + bone scan/PET-CT → biopsy → treatment। Only CA 15-3 rise पर chemotherapy/hormonal therapy शुरू नहीं — imaging confirmation ज़रूरी।

---

✅ Book CA 15-3 Monitoring Panel — With CEA & LFT

For breast cancer treatment monitoring and recurrence surveillance, always combine CA 15-3 with CEA (10–15% higher recurrence sensitivity) and LFT (liver metastases cause LFT elevation alongside CA 15-3). Same NABL-accredited lab every time for serial monitoring:

CA 15-3 + CEA + LFT — Breast Cancer Monitoring Panel CA 15-3 + CEA + SGPT + SGOT + ALP + GGT + Bilirubin + Albumin · NABL-accredited lab · No fasting for CA 15-3/CEA alone (8–12 hrs if LFT included) · Same lab every time for serial results · Home collection · Digital report · Pan-India

Book CA 15-3 Panel →

Affiliate link: I may earn a small commission at no extra cost to you. CA 15-3 monitoring is available free at government cancer centres (Tata Memorial Mumbai, AIIMS Delhi, Kidwai Institute Bangalore, Adyar Cancer Institute Chennai) for registered cancer patients. Never interpret a rising CA 15-3 without imaging confirmation. Never use CA 15-3 as a breast cancer screening test — schedule mammography instead. Always discuss results with your oncologist, not in isolation.

CA 15-3 monitoring Government cancer centres में registered cancer patients के लिए निःशुल्क। Rising CA 15-3 = imaging के बिना interpret नहीं। Screening के लिए CA 15-3 नहीं — mammography schedule करें। Results oncologist से discuss करें।

 Breast Health Support During Treatment

Two supportive products for women undergoing breast cancer treatment or managing breast discomfort — a hot/cold breast therapy pad (for managing the breast discomfort, swelling, and pain that accompany breast cancer surgery, radiation, and treatment-related mastitis or lymphoedema) and EGCG green tea extract (the most studied natural antioxidant with the most promising breast cancer supportive evidence in clinical trials). These are comfort and supportive care tools, not breast cancer treatments. They do not lower CA 15-3 or treat cancer. Always inform your oncologist before starting any supplement during active cancer treatment — EGCG can interact with some chemotherapy regimens.

Large Reusable Breast Therapy Hot & Cold Pads — Momcozy Pink

Managing breast discomfort is an underappreciated but critical aspect of breast cancer treatment quality of life. Several treatment-related conditions cause breast pain and swelling that respond to local hot/cold therapy: Post-surgical pain and swelling (after lumpectomy or mastectomy — cold therapy reduces inflammation and pain in the first 48–72 hours post-surgery); Radiation dermatitis (breast skin becomes red, tender, and irritated during radiotherapy — cold packs provide significant symptom relief); Lymphoedema (arm or breast swelling from lymph node removal — gentle cold therapy helps with the initial inflammatory phase); Treatment-related mastitis or breast infections (warm packs aid in duct expression and reduce inflammation); Breast implant discomfort (post-reconstructive surgery). These reusable gel pads can be used both hot (microwave 20–30 seconds) and cold (freeze for 1–2 hours) — providing flexibility for different clinical needs. The pink colour is intentionally breast cancer awareness themed. Always follow your surgeon's or oncologist's specific instructions regarding when and how to apply heat or cold after breast surgery — cold should not be applied immediately over surgical incisions without physician guidance.

View on Amazon India

Affiliate link — small commission at no extra cost.

Now Foods EGCg Green Tea Extract 400 mg — EGCg 200 mg, 90 Vcap

EGCG (Epigallocatechin gallate) is the principal bioactive catechin in green tea and the most extensively studied polyphenol in breast cancer supportive care research. Clinical and laboratory evidence for EGCG in breast cancer: (1) Antioxidant protection during chemotherapy — EGCG scavenges free radicals generated by chemotherapy-induced oxidative stress, potentially reducing side effects; (2) Aromatase inhibition — EGCG inhibits aromatase enzyme (the same target as letrozole and anastrozole), reducing oestrogen synthesis — relevant for ER-positive breast cancer; (3) Cell cycle arrest — laboratory studies show EGCG induces apoptosis in breast cancer cell lines and inhibits angiogenesis (tumour blood vessel formation); (4) Epidemiological evidence — populations with high green tea consumption (Japan, China) have lower breast cancer incidence; (5) Clinical trials: Japanese trial (Nakachi et al.) found significantly improved recurrence-free survival in early breast cancer patients drinking 3+ cups green tea daily after surgery. Important: EGCG has potential interactions with some chemotherapy agents — always inform your oncologist before starting, particularly if you are on doxorubicin (Adriamycin) or bortezomib. EGCG at high doses may also affect iron absorption — take 2 hours away from iron supplements. 200 mg standardised EGCG per capsule represents approximately 4–5 cups of green tea equivalent.

View on Amazon India

Affiliate link — small commission at no extra cost.

Know a woman with breast cancer who wants to understand her CA 15-3 results? Or a woman anxious about a mildly elevated CA 15-3 from a health checkup? Share this guide. क्या आप किसी breast cancer patient को जानती हैं जो CA 15-3 results समझना चाहती हैं? या कोई health checkup में mildly elevated CA 15-3 से anxious है? यह guide शेयर करें।

Share on WhatsApp

Related Tests / संबंधित जांचें

CA 15-3 के साथ ये जांचें breast cancer monitoring में order की जाती हैं:

CA-125 Test LFT (Liver Function) SGOT / SGPT Serum Calcium (Bone Mets) ALP (Bone / Liver) CBC (Chemo Monitoring) How to Read a Blood Test Report

---

Frequently Asked Questions / अक्सर पूछे जाने वाले सवाल

What is the normal range for CA 15-3?

The normal upper limit for CA 15-3 at most Indian NABL-accredited labs is 25 U/mL (some labs use 30 U/mL as the cut-off — always check your specific lab's reference range). Values below 25–30 U/mL are considered normal. However, what matters far more than any single value is the trend over time — a rising CA 15-3 within the "normal" range (e.g., from 8 to 22 U/mL over 6 months) can be more clinically meaningful than a stable mildly elevated value. Normal CA 15-3 does NOT rule out breast cancer — particularly early-stage (Stage I–II) disease where sensitivity is only 20–30%. For women already diagnosed with breast cancer: the baseline value established at diagnosis is the critical reference point, not the population normal range.

उत्तर: Normal: <25–30 U/mL (lab-dependent)। Single value से trend more important। Rising 8 → 22 (both "normal") = clinically meaningful। Normal CA 15-3 ≠ no breast cancer (especially early-stage: sensitivity 20–30%)। Already diagnosed: baseline = reference point, not population normal।

My health checkup showed CA 15-3 of 42 U/mL. I have no breast symptoms. Should I be alarmed?

A CA 15-3 of 42 U/mL in a healthy woman with no breast symptoms should prompt investigation — not panic. The most likely explanations in order of probability for an Indian woman: (1) Liver disease — check LFT (SGPT, ALP, bilirubin) — hepatitis B, hepatitis C, NAFLD, or cirrhosis are very common benign causes; (2) Benign breast disease — fibrocystic changes are present in 30–50% of premenopausal Indian women and can mildly elevate CA 15-3; (3) Pregnancy or lactation — up to 100 U/mL is physiological; (4) Other benign inflammatory conditions. Breast cancer is possible but less likely at this level without symptoms. Recommended approach: (a) See a gynaecologist or oncologist for clinical breast examination; (b) Get a mammogram (if 40+) or breast ultrasound (if under 40); (c) Check LFT alongside; (d) Recheck CA 15-3 in 6–8 weeks. If CA 15-3 normalises and breast imaging is normal: almost certainly a benign cause. Do not catastrophise a mildly elevated CA 15-3 from a wellness panel.

उत्तर: 42 U/mL + no symptoms = investigation, not panic। Most likely: Liver disease (LFT check), Benign breast disease, Pregnancy/lactation। Action: Clinical breast examination + mammogram/ultrasound + LFT check + 6–8 weeks में recheck। Normalises + normal imaging = almost certainly benign। Wellness panel से mildly elevated = catastrophise नहीं।

I completed breast cancer treatment 1 year ago. My CA 15-3 has risen from 18 to 29 U/mL. Does this mean recurrence?

A rise from 18 to 29 U/mL in a breast cancer survivor is a meaningful change that warrants investigation — but does not confirm recurrence. The 29 U/mL is technically within the normal range at most labs (below 30 U/mL), but a 61% rise above your personal baseline of 18 U/mL (your post-treatment nadir) triggers clinical attention. The clinical protocol: (1) First: repeat CA 15-3 in 4–6 weeks at the same lab to confirm the rise is genuine and not a laboratory fluctuation or biological variation; (2) If the repeat confirms CA 15-3 above 29 U/mL or still rising: proceed to CT chest/abdomen/pelvis and bone scan (or PET-CT); (3) If imaging reveals a suspicious lesion: tissue biopsy to confirm recurrence; (4) Do not start any new treatment based on CA 15-3 alone. Also consider benign explanations: have you had a recent infection, hepatitis flare, or started any new medication? Viral infections and liver inflammation transiently raise CA 15-3.

उत्तर: 18 → 29 = 61% rise above personal baseline — investigation warranted। Protocol: 4–6 weeks बाद same lab पर repeat → confirmed rising → CT + bone scan/PET-CT → suspicious lesion → biopsy। CA 15-3 alone पर treatment शुरू नहीं। Benign: recent infection, hepatitis flare, new medication? Viral infections transiently raise।

How often should CA 15-3 be checked after breast cancer treatment?

The monitoring frequency depends on the breast cancer stage and treatment received. Most major cancer centre protocols in India: (1) During active chemotherapy: CA 15-3 + CEA every 2–3 treatment cycles (approximately every 6–8 weeks); (2) During adjuvant hormone therapy (tamoxifen, aromatase inhibitors for 5–10 years): every 6 months alongside clinical examination and annual mammography; (3) Post-treatment surveillance (years 1–3): every 3–6 months — the highest recurrence risk period; (4) Post-treatment surveillance (years 4–5): every 6 months; (5) Beyond 5 years: annually or as clinically indicated. Important: CA 15-3 surveillance must always be combined with physical examination, mammography, and clinical follow-up — not used as the sole monitoring modality. Many breast cancer recurrences (especially local recurrences) are detected by clinical examination before CA 15-3 rises.

उत्तर: Chemotherapy: हर 6–8 weeks। Hormone therapy: हर 6 months। Post-treatment years 1–3: हर 3–6 months (highest recurrence risk)। Years 4–5: हर 6 months। >5 years: annually। Combined with: physical examination + mammography + clinical follow-up। CA 15-3 alone = sole monitoring नहीं।

Can CA 15-3 be used to diagnose breast cancer if I find a lump?

No — CA 15-3 must never be used to diagnose breast cancer or to decide whether a breast lump requires biopsy. The reasons: (1) CA 15-3 is elevated in only 20–30% of early breast cancer cases — a normal CA 15-3 does not exclude cancer; (2) CA 15-3 is elevated by many benign conditions (liver disease, fibrocystic breast disease, mastitis) that could give a falsely reassuring or falsely alarming result; (3) A breast lump requires definitive evaluation regardless of CA 15-3: clinical examination by a surgeon, imaging (ultrasound of breast and lymph nodes, mammogram if 40+), and if suspicious — core needle biopsy for tissue diagnosis. The gold standard for diagnosing breast cancer is always histopathology (biopsy). If you find a new breast lump in India: see a surgeon at a government or private cancer centre within 2 weeks. Do not delay evaluation based on a normal CA 15-3.

उत्तर: नहीं — CA 15-3 से breast cancer diagnose नहीं। Early cancer में 20–30% sensitivity only। Normal CA 15-3 = cancer exclude नहीं। New breast lump: clinical examination + ultrasound/mammogram + core needle biopsy (suspicious हो तो)। Gold standard = histopathology (biopsy)। Normal CA 15-3 के basis पर evaluation delay नहीं — 2 weeks में surgeon से मिलें।

My CA 15-3 rose slightly in the first month of chemotherapy. Does this mean it is not working?

This is almost certainly the "CA 15-3 flare phenomenon" — a well-recognised and completely normal response to starting effective chemotherapy. When chemotherapy kills tumour cells rapidly in the first 2–6 weeks, the dying cells release large amounts of stored MUC1 (the protein that makes up CA 15-3) into the bloodstream — causing a transient spike. This paradoxical early rise is actually a sign that the chemotherapy is hitting the tumour cells effectively. The flare typically resolves by week 6–8 as the tumour burden decreases. Management: do NOT interpret the early rise as treatment failure; do NOT change chemotherapy at this point. Repeat CA 15-3 at week 6–8. If it is now falling — the initial rise was a flare and treatment is working. Only if CA 15-3 is still rising at 8–12 weeks (confirmed on two measurements) does treatment failure become a clinical concern, warranting CT reassessment.

उत्तर: Almost certainly CA 15-3 flare phenomenon — completely normal। Chemotherapy kills tumour cells → dying cells release MUC1 → transient spike। Flare = sign that chemotherapy hitting tumour cells! Typically resolves by week 6–8। Management: treatment change नहीं। Week 6–8 पर recheck। Falling = flare था, treatment working। Still rising at 8–12 weeks (two measurements) = treatment failure concern → CT reassessment।

---

External References / बाहरी संसाधन

• ASCO — Tumour Markers in Breast Cancer: ASCO 2007 (Updated) Guideline: Tumour Markers in Breast Cancer
• ESMO — Breast Cancer Clinical Practice Guidelines: ESMO 2023 Breast Cancer Clinical Practice Guidelines
• MedlinePlus (NIH): CA 15-3 Test — Patient Information

⚠️ Medical Disclaimer / चिकित्सा अस्वीकरण

This article is for educational purposes only. CA 15-3 must always be interpreted by a qualified oncologist or surgeon alongside imaging, clinical examination, and the patient's complete treatment history. CA 15-3 is not a breast cancer screening test and must not be used to reassure women that they do not have breast cancer — a new breast lump, nipple discharge, or skin change requires prompt clinical evaluation regardless of CA 15-3 value. Never start or change cancer treatment based on CA 15-3 alone without imaging confirmation. Do not take EGCG or any supplement during chemotherapy without informing your oncologist.

यह लेख केवल शैक्षिक है। CA 15-3 को oncologist से imaging + clinical examination के साथ interpret करें। Screening test नहीं — Normal CA 15-3 ≠ no cancer। New breast lump: CA 15-3 value regardless of, clinical evaluation करें। CA 15-3 alone पर treatment change नहीं। EGCG chemotherapy के दौरान: oncologist को inform करें।

Share on WhatsApp